NMDA Side Effects: What Troche Users Need to Know

What the New Clinical Guidance Says

A April 2026 analysis published in Psychiatric Times takes a hard look at the side effect profiles and discontinuation rates across the class of NMDA receptor antagonists used in treatment-resistant depression (TRD)—a category that includes IV ketamine infusions, intranasal esketamine (Spravato), and, increasingly, compounded oral formulations like ketamine troches. The core message from clinicians: depression care is moving too slowly, and providers need to make faster, data-driven decisions about dosing adjustments and medication switches to help patients actually reach remission rather than stalling in partial response.

The analysis highlights that dissociative side effects, cardiovascular fluctuations, and sedation remain the primary drivers of early treatment discontinuation across all NMDA-targeting modalities. Notably, the review emphasizes the importance of structured outcome tracking—specifically PHQ-9 scores and reported side effects at each session—as the evidence-based foundation for deciding when to optimize a dose, extend a treatment interval, or pivot to a different delivery method entirely.

For clinicians managing ketamine patients, this is a call to treat the protocol as a living document, not a fixed schedule. For patients, it's a signal that your experience between sessions matters and that reporting it accurately can directly shape how effectively your treatment is calibrated.

How Troches Fit Into the Side Effect Picture

Understanding where troches land in the NMDA side effect landscape requires a brief comparison across delivery routes. IV infusions produce the most rapid and intense plasma peaks—effective, but also responsible for the strongest dissociative episodes and the highest rates of acute cardiovascular elevation. Intranasal esketamine (Spravato) occupies a middle ground: faster onset than oral routes, but with significant rates of dizziness, nausea, and dissociation that require in-office administration under REMS protocol supervision for at least two hours post-dose.

Compounded ketamine troches, by contrast, are absorbed primarily through the buccal mucosa, producing a slower, more gradual rise in plasma concentration. This pharmacokinetic profile is directly tied to a more manageable side effect experience for many patients. Dissociation tends to be milder and shorter-lived. Nausea is less common than with intranasal routes. Cardiovascular effects are generally more modest. This is why troches have become a preferred at-home maintenance modality—not because they're weaker, but because their slower absorption curve creates a more predictable, titratable experience.

That said, 'milder' doesn't mean 'absent.' The Psychiatric Times analysis is a useful reminder that all NMDA antagonists carry real side effect burdens, and troches are not exempt. Patients using higher-dose troches (commonly in the 200–400mg range depending on their protocol) can still experience meaningful dissociation, perceptual changes, and post-dose fatigue. The key difference is that troche users have more control over their environment and pacing—advantages that should be used deliberately, not taken for granted.

Discontinuation: The Hidden Problem in TRD Treatment

One of the more sobering findings flagged in the review is that discontinuation rates across NMDA antagonist protocols remain high, often due to cumulative side effect burden rather than a single intolerable event. Patients don't always quit because one session went badly—they drop off because mild-to-moderate side effects accumulate over weeks or months without adequate adjustment, leaving them feeling like the trade-off isn't worth it.

For troche patients, this pattern is particularly important to recognize. At-home protocols can create a kind of invisible drift: a patient quietly tolerates increasing nausea or next-day grogginess session after session without flagging it to their prescriber, because nothing feels dramatic enough to report. Meanwhile, their dose, timing, or holding technique may be the culprit—and those are fixable variables. The clinical literature is now explicitly urging providers to close this feedback loop faster, using validated tools like the PHQ-9 alongside direct side effect check-ins at every touchpoint.

If you're on a troche protocol and you're not being asked about side effects at each follow-up, that's a gap worth raising with your provider. The data increasingly supports the idea that reaching remission faster depends on tighter, more responsive calibration—not patience with a suboptimal regimen.

Practical Implications for Troche Dosing and Monitoring

The guidance in this analysis translates into several concrete considerations for patients currently using ketamine troches as part of a TRD treatment plan.

Track your own data between sessions. PHQ-9 self-assessments are freely available and take under two minutes to complete. Logging your scores weekly—not just before appointments—gives both you and your provider a richer picture of your trajectory. Many patients discover their mood fluctuates more than they realized, which can point to timing adjustments or session frequency changes.

Report side effects specifically, not generally. 'I felt kind of off' is less actionable than 'I had about 30 minutes of moderate dissociation, some nausea around the 45-minute mark, and was groggy the next morning.' The more precise your report, the more precisely your protocol can be adjusted. Buccal absorption, hold time, dose size, and session timing are all levers your prescriber can pull—but only if they know what's happening.

Don't conflate tolerability with efficacy. A smoother side effect experience with troches is a feature, but it can also create the false impression that 'nothing is happening.' Some patients unconsciously push for higher doses seeking the dramatic experiences they associate with IV ketamine, when their current dose is actually working therapeutically. Your PHQ-9 score and functional improvement are the right metrics—not intensity of dissociation.

Understand that switching is a legitimate tool. The review's emphasis on faster pivoting between modalities is meaningful for troche patients who plateau. If troches aren't producing adequate remission after a reasonable trial, that's a clinical signal—not a personal failure. IV infusions, intranasal esketamine, or a combination approach may be the right next step, and providers are being encouraged to make those calls sooner rather than waiting months to see if the current approach breaks through.

The Bottom Line for 2026 Troche Protocols

The growing body of clinical literature on NMDA receptor antagonists is gradually refining how ketamine treatment should be managed—and the direction of that refinement favors what troches do well: gradual titration, at-home flexibility, and integration into daily routines rather than isolated clinical events. But the same literature is also clear that flexibility without accountability leads to drift and dropout. The providers and patients getting the best outcomes are those treating every session as a data point and using that data to keep the protocol tightly calibrated. In 2026, that means logging your PHQ-9, reporting your side effects accurately, and expecting your prescriber to act on what you report.